Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CLPT Stock Forecast 2026-2027
$15.15
Current Price
$469.94M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CLPT Price Targets
+98.0%
To High Target of $30.00
+98.0%
To Median Target of $30.00
+65.0%
To Low Target of $25.00
CLPT Price Momentum
-13.4%
1 Week Change
-14.7%
1 Month Change
+37.4%
1 Year Change
+10.7%
Year-to-Date Change
-49.7%
From 52W High of $30.10
+83.2%
From 52W Low of $8.27
📊 TOP ANALYST CALLS
Did CLPT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ClearPoint Neuro is one of their latest high-conviction picks.
Latest CLPT Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, CLPT has a bullish consensus with a median price target of $30.00 (ranging from $25.00 to $30.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $15.15, the median forecast implies a 98.0% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Anderson Schock at B. Riley Securities, projecting a 98.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLPT Analyst Ratings
3
Buy
0
Hold
0
Sell
CLPT Price Target Range
Low
$25.00
Average
$30.00
High
$30.00
Current: $15.15
Latest CLPT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLPT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 18, 2026 | B. Riley Securities | Anderson Schock | Buy | Maintains | $30.00 |
| Mar 18, 2026 | B. Riley Securities | Buy | Maintains | $N/A | |
| Mar 5, 2026 | B. Riley Securities | Buy | Maintains | $N/A | |
| Aug 1, 2025 | Stifel | Buy | Maintains | $N/A | |
| Apr 25, 2025 | B. Riley Securities | Buy | Maintains | $N/A | |
| Apr 1, 2025 | Stifel | Buy | Maintains | $N/A | |
| Jan 28, 2025 | B. Riley Securities | Buy | Maintains | $N/A | |
| Jan 21, 2025 | Lake Street | Buy | Maintains | $N/A | |
| Aug 27, 2024 | Lake Street | Buy | Maintains | $N/A | |
| Mar 13, 2024 | Stifel | Buy | Reiterates | $N/A | |
| Oct 24, 2023 | Stifel | Buy | Initiates | $N/A | |
| Aug 9, 2023 | Lake Street | Buy | Maintains | $N/A | |
| Feb 16, 2023 | B. Riley Securities | Neil Chatterji | Buy | Reinstates | $14.00 |
| Apr 5, 2022 | B. Riley Securities | Marc Wiesenberger | Buy | Reinstates | $15.00 |
| Mar 18, 2021 | Lake Street | Buy | Initiates | $N/A | |
| Jul 17, 2020 | B. Riley Securities | Buy | Initiates | $N/A |
ClearPoint Neuro Inc. (CLPT) Competitors
The following stocks are similar to ClearPoint Neuro based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CLPT
ClearPoint Neuro
mkt cap
524.82M
ClearPoint Neuro Inc. (CLPT) Financial Data
ClearPoint Neuro Inc. has a market capitalization of $469.94M with a P/E ratio of -17.4x. The company generates $40.61M in trailing twelve-month revenue with a -71.6% profit margin.
Revenue growth is +42.9% quarter-over-quarter, while maintaining an operating margin of -69.9% and return on equity of -149.7%.
Valuation Metrics
Market Cap
$469.94M
Enterprise Value
$523.12M
P/E Ratio
-17.4x
PEG Ratio
-0.4x
Price/Sales
11.8x
Growth & Margins
Revenue Growth (YoY)
+42.9%
Gross Margin
+64.0%
Operating Margin
-69.9%
Net Margin
-71.6%
EPS Growth
+42.9%
Financial Health
Cash/Price Ratio
+7.8%
Current Ratio
5.8x
Debt/Equity
337.5x
ROE
-149.7%
ROA
-25.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ClearPoint Neuro Inc. (CLPT) Business Model
About ClearPoint Neuro Inc.
What They Do
Specializes in brain and spine therapy technologies.
Business Model
The company generates revenue by developing and commercializing advanced navigation and delivery systems for neurosurgical procedures. It offers a range of clinical products and pre-clinical development services, allowing for controlled drug and device delivery, which supports various medical applications in neurosurgery.
Additional Information
ClearPoint Neuro has established partnerships with over 90 neurosurgery centers and 60 biologics and drug delivery partners globally. The company has a strong focus on innovation within the neuro space, supported by its Global Training and Innovation Center. Founded in 1998 and based in Solana Beach, California, it plays a critical role in enhancing treatment options for complex neurological disorders.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
172
CEO
Mr. Joseph Michael Burnett
Country
United States
IPO Year
2012
Website
www.clearpointneuro.comClearPoint Neuro Inc. (CLPT) Latest News & Analysis
Latest News
Quick Summary
ClearPoint Neuro (CLPT) shares rose with above-average trading volume, but recent earnings estimate revisions may not lead to further price increases soon.
Why It Matters
ClearPoint Neuro's stock surge and higher trading volume suggest increased investor interest, but revised earnings estimates may indicate potential volatility or stagnation ahead.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
ClearPoint Neuro is a speculative Buy, linked to gene therapy and neurosurgery growth. Recent FDA feedback raises optimism, but risks remain. Q1 growth slowed, cash burn increased, and 2026 revenue guidance disappointed.
Why It Matters
ClearPoint Neuro's speculative buy status reflects potential in gene therapy and neurosurgery, but slowed growth and increased cash burn raise concerns over future profitability and execution risks.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
ClearPoint Neuro, Inc. announced successful preclinical trials for intravenous delivery of large molecule tracers across the blood-brain barrier using its prototype focused ultrasound system.
Why It Matters
ClearPoint Neuro's successful trial positions it in the focused ultrasound market, potentially enhancing its product offerings and attracting investment interest, impacting stock performance positively.
Source: Accesswire
Market Sentiment:
Neutral
ClearPoint Neuro Q1 Earnings Call Highlights
2 months ago
Quick Summary
ClearPoint Neuro (NASDAQ: CLPT) reported record Q1 2026 revenue, reaffirming its full-year outlook, driven by growth in its neurosurgical devices and contributions from the IRRAflow acquisition.
Why It Matters
ClearPoint Neuro's record revenue signals strong business performance and growth potential, reassuring investors about its financial health and future prospects in the neurosurgery market.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
ClearPoint Neuro, Inc. (CLPT) held its Q1 2026 earnings call, discussing financial performance and strategic updates. Further details can be found in the complete transcript.
Why It Matters
ClearPoint Neuro's Q1 2026 earnings call provides insights into financial performance, growth strategies, and market positioning, which can influence stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
ClearPoint Neuro Reports First Quarter 2026 Results
2 months ago
Quick Summary
ClearPoint Neuro reported Q1 2026 revenue of $12.1M, a 43% increase. Key achievements include FDA clearance for a new surgical drill and expansion in global centers to over 175.
Why It Matters
ClearPoint Neuro's record revenue and significant organic growth indicate strong market demand and operational efficiency, boosting investor confidence in future performance and potential returns.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About CLPT Stock
What is ClearPoint Neuro Inc.'s (CLPT) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, ClearPoint Neuro Inc. (CLPT) has a median price target of $30.00. The highest price target is $30.00 and the lowest is $25.00.
Is CLPT stock a good investment in 2027?
According to current analyst ratings, CLPT has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $15.15. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CLPT stock?
Wall Street analysts predict CLPT stock could reach $30.00 in the next 12 months. This represents a 98.0% increase from the current price of $15.15. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ClearPoint Neuro Inc.'s business model?
The company generates revenue by developing and commercializing advanced navigation and delivery systems for neurosurgical procedures. It offers a range of clinical products and pre-clinical development services, allowing for controlled drug and device delivery, which supports various medical applications in neurosurgery.
What is the highest forecasted price for CLPT ClearPoint Neuro Inc.?
The highest price target for CLPT is $30.00 from Anderson Schock at B. Riley Securities, which represents a 98.0% increase from the current price of $15.15.
What is the lowest forecasted price for CLPT ClearPoint Neuro Inc.?
The lowest price target for CLPT is $25.00 from at , which represents a 65.0% increase from the current price of $15.15.
What is the overall CLPT consensus from analysts for ClearPoint Neuro Inc.?
The overall analyst consensus for CLPT is bullish. Out of 4 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are CLPT stock price projections?
Stock price projections, including those for ClearPoint Neuro Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:16 AM UTC